Could a simple dose change make a tough cancer drug easier to take?
NCT ID NCT05263050
First seen Jun 25, 2026 · Last updated Jul 29, 2026 · Updated 3 times
Summary
This Phase II trial is testing whether a different dosing schedule of the drug cabozantinib can reduce side effects while still controlling cancer growth. It includes people with advanced kidney cancer (clear cell or non-clear cell) and neuroendocrine tumors (including carcinoid). Some participants will also receive the immunotherapy nivolumab. The goal is to find a dose that patients can tolerate better, without losing effectiveness.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Cabozantinib (a targeted cancer drug) and nivolumab (an immunotherapy)
- What this could lead to
- If successful, this could lead to a better-tolerated dosing schedule for cabozantinib, potentially improving quality of life and treatment outcomes for people with advanced kidney cancer or neuroendocrine tumors.
- What could go wrong
- This is a mid-stage (Phase II) trial with only 111 participants, so results may not apply to everyone. The new dosing might not reduce side effects or improve survival as hoped.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CARCINOID TUMOR are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Fox Chase Cancer Center
RECRUITINGPhiladelphia, Pennsylvania, 19111, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- One dose may not fit all: blood tests could tailor cancer drug dosing
- Can a pill boost the immune system to fight Hard-to-Treat cancers?
- Can a new 'Nanobody' tracer outsmart standard scans for neuroendocrine cancers?
- Can a Three-Drug cocktail shrink Hard-to-Treat neuroendocrine tumors?
- Old drug, new hope: mercaptopurine tested against rare cancer syndrome
- Experimental drug targets Hard-to-Treat neuroendocrine cancers